|
MX3864E
(es)
*
|
1975-05-27 |
1981-08-26 |
Syntex Corp |
Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
|
|
US4933168A
(en)
*
|
1975-05-27 |
1990-06-12 |
Syntex Pharmaceuticals International Limited |
Stable, crystalline flunisolide
|
|
GB1571629A
(en)
*
|
1977-11-30 |
1980-07-16 |
Fisons Ltd |
Pharmaceutical compositions containing beclomethasone dipropionate
|
|
IT1121513B
(it)
*
|
1979-05-28 |
1986-04-02 |
Chiesi Farma Spa |
Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
|
|
ATE3774T1
(de)
*
|
1980-05-02 |
1983-06-15 |
Schering Corporation |
Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung.
|
|
FI63672C
(fi)
*
|
1980-05-19 |
1983-08-10 |
Orion Yhtymae Oy |
Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
|
|
KR890000664B1
(ko)
*
|
1981-10-19 |
1989-03-22 |
바리 안소니 뉴우샘 |
미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
|
|
GB8432063D0
(en)
*
|
1984-12-19 |
1985-01-30 |
Riker Laboratories Inc |
Physically modified steroids
|
|
US5962490A
(en)
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US5562608A
(en)
*
|
1989-08-28 |
1996-10-08 |
Biopulmonics, Inc. |
Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
|
|
US5736509A
(en)
*
|
1990-12-14 |
1998-04-07 |
Texas Biotechnology Corporation |
Cyclic peptide surface feature mimics of endothelin
|
|
US5658549A
(en)
*
|
1991-12-12 |
1997-08-19 |
Glaxo Group Limited |
Aerosol formulations containing propellant 134a and fluticasone propionate
|
|
US5736124A
(en)
*
|
1991-12-12 |
1998-04-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicament
|
|
IL104068A
(en)
|
1991-12-12 |
1998-10-30 |
Glaxo Group Ltd |
Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
|
|
US5916540A
(en)
|
1994-10-24 |
1999-06-29 |
Glaxo Group Limited |
Aerosol formulations containing P134A and/or P227 and particulate medicament
|
|
US5674471A
(en)
*
|
1991-12-12 |
1997-10-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and salbutamol
|
|
US5653962A
(en)
*
|
1991-12-12 |
1997-08-05 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicaments
|
|
US5744123A
(en)
*
|
1991-12-12 |
1998-04-28 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicaments
|
|
DK0616524T3
(da)
|
1991-12-12 |
1999-06-21 |
Glaxo Group Ltd |
Lægemidler
|
|
US7101534B1
(en)
|
1991-12-18 |
2006-09-05 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
|
US7105152B1
(en)
|
1991-12-18 |
2006-09-12 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
|
US5301664A
(en)
*
|
1992-03-06 |
1994-04-12 |
Sievers Robert E |
Methods and apparatus for drug delivery using supercritical solutions
|
|
ATE222754T1
(de)
*
|
1992-06-12 |
2002-09-15 |
Teijin Ltd |
Ultrafeines pulver zur inhalation und dessen herstellung
|
|
MX9304585A
(es)
|
1992-07-31 |
1994-03-31 |
Glaxo Group Ltd |
Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
|
|
WO1994022427A1
(en)
*
|
1993-04-01 |
1994-10-13 |
Amgen Inc. |
Method for preparing drugs to treat dermal disorders
|
|
US6376523B1
(en)
|
1994-05-20 |
2002-04-23 |
Texas Biotechnology Corporation |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6030991A
(en)
*
|
1993-05-20 |
2000-02-29 |
Texas Biotechnology Corp. |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6541498B2
(en)
|
1993-05-20 |
2003-04-01 |
Texas Biotechnology |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
|
US6613804B2
(en)
|
1993-05-20 |
2003-09-02 |
Encysive Pharmaceuticals, Inc. |
Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
|
JP3119487B2
(ja)
|
1994-08-09 |
2000-12-18 |
シェーリング コーポレイション |
ベクロメタゾンジプロピオネートフレオン（登録商標）包接化合物の調製プロセス
|
|
US5980949A
(en)
*
|
1994-10-03 |
1999-11-09 |
Astra Aktiebolag |
Formulation for inhalation
|
|
US5983956A
(en)
*
|
1994-10-03 |
1999-11-16 |
Astra Aktiebolag |
Formulation for inhalation
|
|
US5863902A
(en)
*
|
1995-01-06 |
1999-01-26 |
Sibia Neurosciences, Inc. |
Methods of treating neurodegenerative disorders using protease inhibitors
|
|
US5804560A
(en)
*
|
1995-01-06 |
1998-09-08 |
Sibia Neurosciences, Inc. |
Peptide and peptide analog protease inhibitors
|
|
US5646130A
(en)
*
|
1995-06-30 |
1997-07-08 |
Ocean University Of Oingdao |
Low molecular weight sulfated polysaccharides and uses thereof
|
|
US5977117A
(en)
*
|
1996-01-05 |
1999-11-02 |
Texas Biotechnology Corporation |
Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
|
|
US5700487A
(en)
*
|
1996-03-04 |
1997-12-23 |
The Ohio State University |
Treatment of pulmonary inflammation
|
|
US5958905A
(en)
*
|
1996-03-26 |
1999-09-28 |
Texas Biotechnology Corporation |
Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
|
|
US5804585A
(en)
*
|
1996-04-15 |
1998-09-08 |
Texas Biotechnology Corporation |
Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
|
|
ATE345682T1
(de)
*
|
1996-05-01 |
2006-12-15 |
Imarx Pharmaceutical Corp |
In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
|
|
US6416960B1
(en)
|
1996-08-08 |
2002-07-09 |
Prolume, Ltd. |
Detection and visualization of neoplastic tissues and other tissues
|
|
US6380222B2
(en)
|
1996-10-11 |
2002-04-30 |
Astrazeneca Ab |
Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
|
|
SE9603725D0
(sv)
*
|
1996-10-11 |
1996-10-11 |
Astra Ab |
New teatment
|
|
JP3795533B2
(ja)
|
1996-12-12 |
2006-07-12 |
プロルーム・リミテツド |
感染性物質を検出及び同定するための方法及び装置
|
|
SE9700135D0
(sv)
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
|
SE9700133D0
(sv)
*
|
1997-01-20 |
1997-01-20 |
Astra Ab |
New formulation
|
|
TR200101905T2
(tr)
|
1997-04-28 |
2002-06-21 |
Texas Biotechnology Corporation |
Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler.
|
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
|
US6342611B1
(en)
*
|
1997-10-10 |
2002-01-29 |
Cytovia, Inc. |
Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
|
|
US6362009B1
(en)
|
1997-11-21 |
2002-03-26 |
Merck & Co., Inc. |
Solid phase synthesis of heterocycles
|
|
WO1999040771A2
(en)
|
1998-02-13 |
1999-08-19 |
Selective Genetics, Inc. |
Concurrent flow mixing for preparing compositions comprising gene therapy vectors
|
|
EP1925320A3
(en)
|
1998-03-27 |
2008-09-03 |
Prolume, Ltd. |
Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
|
|
WO2000004914A1
(en)
*
|
1998-07-21 |
2000-02-03 |
Cytovia, Inc. |
Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
|
|
US6667299B1
(en)
*
|
2000-03-16 |
2003-12-23 |
Hollis-Eden Pharmaceuticals, Inc. |
Pharmaceutical compositions and treatment methods
|
|
AU1624801A
(en)
|
1999-11-19 |
2001-05-30 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists related applications
|
|
US6638977B1
(en)
|
1999-11-19 |
2003-10-28 |
Corvas International, Inc. |
Plasminogen activator inhibitor antagonists
|
|
US7897140B2
(en)
|
1999-12-23 |
2011-03-01 |
Health Research, Inc. |
Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
|
|
BR0016821A
(pt)
|
1999-12-31 |
2002-12-10 |
Texas Biotechnology Corp |
Sulfonamidas e derivados da mesma que modulam a atividade de endotelina
|
|
US7109315B2
(en)
|
2000-03-15 |
2006-09-19 |
Bruce J. Bryan |
Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
|
|
US6485707B2
(en)
|
2001-02-15 |
2002-11-26 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
US6544497B2
(en)
|
2001-02-15 |
2003-04-08 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
US6596262B2
(en)
|
2001-02-15 |
2003-07-22 |
Aeropharm Technology Incorporated |
Modulated release particles for aerosol delivery
|
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
|
US20030129203A1
(en)
*
|
2001-08-27 |
2003-07-10 |
Nautilus Biotech S.A. |
Mutant recombinant adeno-associated viruses
|
|
CA2463724A1
(en)
*
|
2001-10-16 |
2003-04-24 |
Structural Bioinformatics Inc. |
Organosulfur inhibitors of tyrosine phosphatases
|
|
AUPR868201A0
(en)
*
|
2001-11-05 |
2001-11-29 |
Thorlock International Limited |
Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
|
|
US6696473B2
(en)
*
|
2001-12-21 |
2004-02-24 |
X-Ceptor Therapeutics, Inc. |
Heterocyclic modulators of nuclear receptors
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
US7998986B2
(en)
|
2001-12-21 |
2011-08-16 |
Exelixis Patent Company Llc |
Modulators of LXR
|
|
US7582284B2
(en)
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
|
US20030199594A1
(en)
*
|
2002-04-23 |
2003-10-23 |
Rasik Shah |
Helium propellant composition for use with aerosols
|
|
US20040001801A1
(en)
*
|
2002-05-23 |
2004-01-01 |
Corvas International, Inc. |
Conjugates activated by cell surface proteases and therapeutic uses thereof
|
|
CA2490692A1
(en)
|
2002-06-27 |
2004-01-08 |
Health Research, Inc. |
Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
|
|
EP1606291A2
(en)
|
2002-07-02 |
2005-12-21 |
Health Research, Inc. |
Efficient synthesis of pyropheophorbide a and its dervatives
|
|
AU2003263552A1
(en)
*
|
2002-09-09 |
2004-03-29 |
Nautilus Biotech |
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
|
US20060020396A1
(en)
*
|
2002-09-09 |
2006-01-26 |
Rene Gantier |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
US20050202438A1
(en)
*
|
2002-09-09 |
2005-09-15 |
Rene Gantier |
Rational directed protein evolution using two-dimensional rational mutagenesis scanning
|
|
US7094807B2
(en)
*
|
2002-11-19 |
2006-08-22 |
Achillion Pharmaceuticals, Inc. |
Substituted aryl thioureas and related compounds; inhibitors of viral replication
|
|
EP1575648A4
(en)
*
|
2002-12-18 |
2007-07-04 |
Glaxo Group Ltd |
DRUG DELIVERY SYSTEM WITH A VENTILATED MOUTHPIECE
|
|
EP2311973A1
(en)
|
2003-03-05 |
2011-04-20 |
Halozyme, Inc. |
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US7244739B2
(en)
*
|
2003-05-14 |
2007-07-17 |
Torreypines Therapeutics, Inc. |
Compounds and uses thereof in modulating amyloid beta
|
|
ATE439837T1
(de)
*
|
2003-06-03 |
2009-09-15 |
Novartis Ag |
5-gliedrige heterocyclische p-38 inhibitoren
|
|
EP1911754B1
(en)
|
2003-08-13 |
2013-10-09 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US7420000B2
(en)
|
2003-09-10 |
2008-09-02 |
University Of Southern California |
Amino phosphonate and amino bis-phosphonate derivatives
|
|
US20050148534A1
(en)
*
|
2003-09-22 |
2005-07-07 |
Castellino Angelo J. |
Small molecule compositions and methods for increasing drug efficiency using compositions thereof
|
|
WO2005090370A1
(en)
*
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
|
US8519158B2
(en)
*
|
2004-03-12 |
2013-08-27 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
|
CN101198598A
(zh)
|
2004-05-20 |
2008-06-11 |
弗尔德里克斯制药股份有限公司 |
2-((杂)芳基)-苯并噁唑化合物及其衍生物、组合物以及用于稳定和抑制甲状腺素转运蛋白错重叠的方法
|
|
JP2008503490A
(ja)
*
|
2004-06-17 |
2008-02-07 |
センジェント・セラピューティクス・インコーポレイテッド |
チロシンホスファターゼの三置換窒素調節物質
|
|
EP1786421A2
(en)
*
|
2004-07-09 |
2007-05-23 |
Cengent Therapeutics, Inc. |
Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
|
|
EA200700225A1
(ru)
|
2004-07-12 |
2008-02-28 |
Айдан Фармасьютикалз, Инк. |
Аналоги тетрапептида
|
|
WO2006028970A1
(en)
*
|
2004-09-02 |
2006-03-16 |
Cengent Therapeutics, Inc. |
Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
|
|
NZ554545A
(en)
|
2004-09-17 |
2010-10-29 |
Whitehead Inst Of Biomedical R |
Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
|
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
|
WO2006068978A2
(en)
|
2004-12-21 |
2006-06-29 |
Takeda Pharmaceutial Company Limited |
Dipeptidyl peptidase inhibitors
|
|
US8222257B2
(en)
|
2005-04-01 |
2012-07-17 |
The Regents Of The University Of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
|
US20060251619A1
(en)
*
|
2005-05-04 |
2006-11-09 |
Gilles Borrelly |
Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
|
|
CN101137655A
(zh)
|
2005-06-17 |
2008-03-05 |
配体药物公司 |
雄激素受体调节剂化合物和方法
|
|
WO2007002109A2
(en)
*
|
2005-06-20 |
2007-01-04 |
The Regents Of The University Of California |
Multidentate pyrone-derived chelators for medicinal imaging and chelation
|
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
AU2006304804B2
(en)
*
|
2005-10-21 |
2011-06-02 |
Vertex Pharmaceuticals Incorporated |
Modified proteases that inhibit complement activation
|
|
US8138361B2
(en)
*
|
2005-12-28 |
2012-03-20 |
The Trustees Of The University Of Pennsylvania |
C-10 carbamates of taxanes
|
|
MX2008011633A
(es)
*
|
2006-03-13 |
2008-12-16 |
Activx Biosciences Inc |
Aminoquinolonas como inhibidores de gsk-3.
|
|
US20080038224A1
(en)
*
|
2006-03-28 |
2008-02-14 |
Thierry Guyon |
Modified interferon-beta (IFN-beta) polypeptides
|
|
EA200870385A1
(ru)
*
|
2006-03-29 |
2009-04-28 |
Фолдркс Фармасьютикалз, Инк. |
Ингибирование токсичности альфа-синуклеина
|
|
US20070286814A1
(en)
*
|
2006-06-12 |
2007-12-13 |
Medispray Laboratories Pvt. Ltd. |
Stable aerosol pharmaceutical formulations
|
|
US8383388B2
(en)
|
2006-06-19 |
2013-02-26 |
Catalyst Biosciences, Inc. |
Modified coagulation factor IX polypeptides and use thereof for treatment
|
|
NZ596091A
(en)
|
2006-08-28 |
2012-07-27 |
Jolla Inst Allergy Immunolog |
Antagonistic human light-specific human monoclonal antibodies
|
|
PT2066662E
(pt)
|
2006-09-21 |
2013-02-13 |
Kyorin Seiyaku Kk |
Inibidores de serina-hidrolase
|
|
EP2145877B1
(en)
|
2006-10-09 |
2012-10-03 |
Takeda Pharmaceutical Company Limited |
Aurora Kinase inhibitors
|
|
EP2223925A1
(en)
|
2006-10-09 |
2010-09-01 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
EP2113500A1
(en)
|
2006-10-31 |
2009-11-04 |
Takeda Pharmaceutical Company Limited |
MAPK/ERK kinase inhibitors
|
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
|
CN101678079B
(zh)
|
2006-11-28 |
2013-12-25 |
韩诺生物制约株式会社 |
修饰的促红细胞生成素多肽及其治疗用途
|
|
WO2009070164A1
(en)
|
2007-11-28 |
2009-06-04 |
University Of Central Florida |
Vigor enhancement via administration of pyrimidine derivatives
|
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
|
WO2008079371A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Encysive Pharmaceuticals, Inc. |
Modulators of c3a receptor and methods of use thereof
|
|
JP5825757B2
(ja)
|
2007-02-11 |
2015-12-02 |
マップ・ファーマシューティカルズ・インコーポレイテッド |
副作用プロファイルを最小限にしながら片頭痛の迅速な緩和を可能にするｄｈｅの治療上の投与方法
|
|
EP2144604B1
(en)
|
2007-02-28 |
2011-09-21 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of chronic viral hepatitis C using RO 113-0830
|
|
US8389514B2
(en)
*
|
2007-09-11 |
2013-03-05 |
Kyorin Pharmaceutical Co., Ltd. |
Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors
|
|
JP5373799B2
(ja)
|
2007-09-12 |
2013-12-18 |
杏林製薬株式会社 |
Ｇｓｋ−３阻害剤としてのスピロ環式アミノキノロン
|
|
ES2488966T3
(es)
|
2007-09-25 |
2014-09-01 |
Takeda Pharmaceutical Company Limited |
Inhibidores de cinasa de tipo Polo
|
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
|
US8426587B2
(en)
*
|
2007-11-21 |
2013-04-23 |
Pharmaxis Ltd. |
Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor
|
|
ES2413504T3
(es)
|
2007-12-21 |
2013-07-16 |
Ligand Pharmaceuticals Inc. |
Moduladores selectivos del receptor de andrógeno (SARM) y usos de los mismos
|
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
|
AU2009236635B2
(en)
|
2008-04-14 |
2014-02-13 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
|
EP2303886A2
(en)
|
2008-06-24 |
2011-04-06 |
Takeda Pharmaceutical Company Limited |
Pi3k/m tor inhibitors
|
|
EP2318035B1
(en)
|
2008-07-01 |
2019-06-12 |
Curemark, Llc |
Methods and compositions for the treatment of symptoms of neurological and mental health disorders
|
|
DK3037529T3
(da)
|
2008-12-09 |
2019-05-20 |
Halozyme Inc |
Udvidede opløselige ph20-polypeptider og anvendelse deraf
|
|
WO2010080830A1
(en)
|
2009-01-06 |
2010-07-15 |
Curemark Llc |
Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
|
|
BRPI1007379B8
(pt)
|
2009-01-06 |
2022-07-19 |
Curemark Llc |
composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
|
|
EP2403523A1
(en)
|
2009-03-06 |
2012-01-11 |
Halozyme, Inc. |
Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
|
|
US8071591B2
(en)
*
|
2009-03-11 |
2011-12-06 |
Kyorin Pharmaceutical Co., Ltd. |
7-cycloalkylaminoquinolones as GSK-3 inhibitors
|
|
WO2010111626A2
(en)
|
2009-03-27 |
2010-09-30 |
Takeda Pharmaceutical Company Limited |
Poly (adp-ribose) polymerase (parp) inhibitors
|
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
|
EP2459561A1
(en)
|
2009-07-30 |
2012-06-06 |
Takeda Pharmaceutical Company Limited |
Poly (adp-ribose) polymerase (parp) inhibitors
|
|
WO2011041293A1
(en)
|
2009-09-30 |
2011-04-07 |
Takeda Pharmaceutical Company Limited |
Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
|
|
US8871460B2
(en)
|
2009-11-09 |
2014-10-28 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
|
WO2011069002A1
(en)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
US8710092B2
(en)
*
|
2009-12-23 |
2014-04-29 |
Map Pharmaceuticals, Inc. |
Substituted indolo 4,3 FG quinolines useful for treating migraine
|
|
CA2784799C
(en)
|
2009-12-30 |
2014-06-10 |
Shanghai Fochon Pharmaceutical Co Ltd |
Certain dipeptidyl peptidase inhibtors
|
|
CN102834393B
(zh)
|
2010-02-03 |
2015-07-22 |
武田药品工业株式会社 |
细胞凋亡信号调节激酶1抑制剂
|
|
JP6069661B2
(ja)
|
2010-06-24 |
2017-02-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
|
|
BR112013027034A8
(pt)
|
2011-04-21 |
2018-01-02 |
Curemark Llc |
"compostos para o tratamento de transtornos neuropsiquiátricos."
|
|
US8604035B2
(en)
|
2011-06-23 |
2013-12-10 |
Map Pharmaceuticals, Inc. |
Fluoroergoline analogs
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
AU2012355982A1
(en)
|
2011-12-19 |
2014-07-10 |
Map Pharmaceuticals, Inc. |
Novel iso-ergoline derivatives
|
|
EP2793583A4
(en)
|
2011-12-21 |
2015-08-12 |
Map Pharmaceuticals Inc |
NOVEL NEUROMODULATORY CONNECTIONS
|
|
JP6067746B2
(ja)
|
2011-12-30 |
2017-01-25 |
ハロザイム インコーポレイテッド |
Ｐｈ２０ポリペプチド変異体、その製剤および使用
|
|
ES2899730T3
(es)
|
2012-03-07 |
2022-03-14 |
Mclean Hospital Corp |
Derivados de la aminoquinolina y sus usos
|
|
US9913822B2
(en)
|
2012-04-04 |
2018-03-13 |
Halozyme, Inc. |
Combination therapy with an anti-hyaluronan agent and therapeutic agent
|
|
TR201807453T4
(tr)
|
2012-05-02 |
2018-06-21 |
Boehringer Ingelheim Int |
Ssao'nun sübstitüe 3-haloallilamin inhibitörleri ve bunların kullanımları.
|
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
|
WO2013187965A1
(en)
|
2012-06-14 |
2013-12-19 |
Mayo Foundation For Medical Education And Research |
Pyrazole derivatives as inhibitors of stat3
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
US9074186B2
(en)
|
2012-08-15 |
2015-07-07 |
Boston Medical Center Corporation |
Production of red blood cells and platelets from stem cells
|
|
EP2934143A4
(en)
|
2012-12-21 |
2016-06-15 |
Map Pharmaceuticals Inc |
NOVEL DERIVATIVES OF METHYSERGIDE
|
|
WO2014107745A1
(en)
|
2013-01-07 |
2014-07-10 |
Halozyme, Inc. |
Metal sensitive mutants of matrix metalloproteases and uses thereof
|
|
CA2902232C
(en)
|
2013-02-22 |
2020-12-29 |
University Of Southern California |
Methods for treatment of ophthalmic diseases and disorders
|
|
EP2968296B1
(en)
|
2013-03-12 |
2020-09-02 |
The Regents of the University of California |
Gamma-secretase modulators
|
|
WO2014145331A1
(en)
|
2013-03-15 |
2014-09-18 |
University Of Southern California |
Methods, compounds, and compositions for the treatment of angiotensin-related diseases
|
|
EP3003390B1
(en)
|
2013-06-06 |
2021-07-07 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
EP3094323A4
(en)
|
2014-01-17 |
2017-10-11 |
Ligand Pharmaceuticals Incorporated |
Methods and compositions for modulating hormone levels
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
CN106470679A
(zh)
|
2014-05-12 |
2017-03-01 |
科内图斯医药公司 |
用半胱天冬酶抑制剂治疗慢性肝脏疾病并发症
|
|
CA2949998A1
(en)
|
2014-05-28 |
2015-12-03 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
CA3203273A1
(en)
|
2014-10-14 |
2016-04-21 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
EP3209658A1
(en)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
CN107406423B
(zh)
|
2014-10-31 |
2020-06-16 |
通用医疗公司 |
强效γ-分泌酶调节剂
|
|
DK3333191T3
(da)
|
2014-12-11 |
2020-10-26 |
Pf Medicament |
Anti-C10ORF54-antistoffer og anvendelser deraf
|
|
WO2016106221A1
(en)
|
2014-12-22 |
2016-06-30 |
The Rockefeller University |
Anti-mertk agonistic antibodies and uses thereof
|
|
CN107428745A
(zh)
|
2015-01-20 |
2017-12-01 |
Xoc制药股份有限公司 |
麦角灵化合物及其用途
|
|
EP3247357A4
(en)
|
2015-01-20 |
2018-07-11 |
Xoc Pharmaceuticals, Inc |
Isoergoline compounds and uses thereof
|
|
RU2725221C2
(ru)
|
2015-03-03 |
2020-06-30 |
Кимаб Лимитед |
Антитела, их применение и способы применения
|
|
WO2016176617A2
(en)
|
2015-04-29 |
2016-11-03 |
New York University |
Method for treating high-grade gliomas
|
|
CN107849144B
(zh)
|
2015-05-29 |
2021-09-17 |
艾吉纳斯公司 |
抗-ctla-4抗体及其使用方法
|
|
PT3640345T
(pt)
|
2015-08-17 |
2021-12-29 |
Kura Oncology Inc |
Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
|
|
WO2017040790A1
(en)
|
2015-09-01 |
2017-03-09 |
Agenus Inc. |
Anti-pd-1 antibodies and methods of use thereof
|
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
|
EP4455145A3
(en)
|
2015-12-02 |
2025-03-12 |
Astraea Therapeutics, LLC |
Piperidinyl nociceptin receptor compounds
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
WO2017117478A1
(en)
|
2015-12-31 |
2017-07-06 |
Conatus Pharmaceuticals Inc. |
Methods of using caspase inhibitors in treatment of liver disease
|
|
KR20180095094A
(ko)
|
2016-01-08 |
2018-08-24 |
셀진 코포레이션 |
암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
|
|
WO2017120422A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Antiproliferative compounds, and their pharmaceutical compositions and uses
|
|
EP3399981B1
(en)
|
2016-01-08 |
2023-08-02 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
|
US10960013B2
(en)
|
2016-03-04 |
2021-03-30 |
East Carolina University |
J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
|
|
WO2017156191A1
(en)
|
2016-03-08 |
2017-09-14 |
Los Gatos Pharmaceuticals, Inc. |
Composite nanoparticles and uses thereof
|
|
US10407437B2
(en)
|
2016-03-08 |
2019-09-10 |
Los Gatos Pharmaceuticals, Inc. |
Camptothecin derivatives and uses thereof
|
|
WO2017180794A1
(en)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
|
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
DK3454904T3
(da)
|
2016-05-13 |
2023-02-06 |
Pasteur Institut |
Inhibering af beta-2-nikotiniske acetylcholinreceptorer til at behandle patologi ved Alzheimers sygdom
|
|
AU2017271588B2
(en)
|
2016-05-27 |
2022-01-20 |
Agenus Inc. |
Anti-TIM-3 antibodies and methods of use thereof
|
|
MA45602A
(fr)
|
2016-07-08 |
2019-05-15 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs méthodes d'utilisation
|
|
WO2018035281A1
(en)
|
2016-08-17 |
2018-02-22 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
|
BR112019007369A2
(pt)
|
2016-10-11 |
2019-07-16 |
Agenus Inc |
anticorpos anti-lag-3 e métodos de uso dos mesmos
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
EP3534885B1
(en)
|
2016-11-03 |
2021-01-20 |
Kura Oncology, Inc. |
Farnesyltransferase inhibitors for use in treating cancer
|
|
AU2017353939B2
(en)
|
2016-11-07 |
2025-01-30 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
US10836774B2
(en)
|
2016-11-30 |
2020-11-17 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
|
KR102603681B1
(ko)
|
2016-12-07 |
2023-11-17 |
아게누스 인코포레이티드 |
항체 및 이의 사용방법
|
|
PT3551660T
(pt)
|
2016-12-07 |
2023-11-30 |
Ludwig Inst For Cancer Res Ltd |
Anticorpos anti-ctla-4 e métodos de uso dos mesmos
|
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
TWI693074B
(zh)
|
2017-02-21 |
2020-05-11 |
美商庫拉腫瘤技術股份有限公司 |
以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
|
|
WO2018191233A1
(en)
|
2017-04-10 |
2018-10-18 |
Curemark, Llc |
Compositions for treating addiction
|
|
AU2018253176B2
(en)
|
2017-04-13 |
2023-02-02 |
Agenus Inc. |
Anti-CD137 antibodies and methods of use thereof
|
|
WO2018193427A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
|
EP4275698A3
(en)
|
2017-05-01 |
2024-05-15 |
Agenus Inc. |
Anti-tigit antibodies and methods of use thereof
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
WO2018223065A1
(en)
|
2017-06-01 |
2018-12-06 |
Xoc Pharmaceuticals, Inc. |
Ergoline derivatives for use in medicine
|
|
SG10202110492YA
(en)
|
2017-06-22 |
2021-11-29 |
Catalyst Biosciences Inc |
Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
|
|
WO2019002228A1
(en)
|
2017-06-26 |
2019-01-03 |
Institut Pasteur |
TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
|
|
EP3645044A4
(en)
|
2017-06-27 |
2021-04-28 |
Neuracle Science Co., Ltd |
USE OF ANTIBODIES DIRECTED AGAINST A 19-SEQUENCE-LIKE FAMILY, MEMBER A5, FOR THE TREATMENT OF GLAUCOMA
|
|
WO2019003165A1
(en)
|
2017-06-27 |
2019-01-03 |
Neuracle Science Co., Ltd. |
ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
|
|
KR20220031738A
(ko)
|
2017-06-27 |
2022-03-11 |
주식회사 뉴라클사이언스 |
암 치료를 위한 항-fam19a5 항체의 용도
|
|
CN111344011B
(zh)
|
2017-06-27 |
2024-01-26 |
纽洛可科学有限公司 |
抗fam19a5抗体用于治疗纤维化的用途
|
|
CA3069523A1
(en)
|
2017-07-11 |
2019-01-17 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2019032489A1
(en)
|
2017-08-07 |
2019-02-14 |
Kura Oncology, Inc. |
METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
|
|
AU2018324070B2
(en)
|
2017-09-01 |
2023-05-18 |
East Carolina University |
Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
|
|
EP3692171A4
(en)
|
2017-10-02 |
2021-06-23 |
Neuracle Science Co., Ltd |
USING ANTI-FAMILY WITH SEQUENCE LIKE 19, ELEMENT A5 ANTIBODIES FOR TREATMENT AND DIAGNOSIS OF MENTAL DISORDERS
|
|
JP7039694B2
(ja)
|
2017-10-31 |
2022-03-22 |
スターテン・バイオテクノロジー・ベー・フェー |
抗ａｐｏｃ３抗体およびその使用方法
|
|
US20190216751A1
(en)
|
2017-11-15 |
2019-07-18 |
California State University Northridge |
Compositions and Methods for the Treatment and Prevention of Cancer
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
EP3823986A4
(en)
|
2018-04-24 |
2022-03-23 |
Neuracle Science Co., Ltd |
USE OF ANTIBODIES AGAINST FAMILY SEQUENCE 19, ITEM A5 IN THE TREATMENT OF NEUROPATHIC PAIN
|
|
EP3790979A4
(en)
|
2018-05-08 |
2022-04-27 |
Neuracle Science Co., Ltd |
RELEASE OF ADENO-ASSOCIATED VIRUS (AAV) FROM ANTI-FAM19A5 ANTIBODIES
|
|
US11970532B2
(en)
|
2018-05-10 |
2024-04-30 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
|
CA3105352A1
(en)
|
2018-06-29 |
2020-01-02 |
Histogen, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
|
KR102869944B1
(ko)
|
2018-07-11 |
2025-10-15 |
액팀 테라퓨틱스, 인코퍼레이티드 |
조작된 면역자극성 박테리아 균주 및 이의 용도
|
|
US20230243836A1
(en)
|
2018-07-20 |
2023-08-03 |
Pierre Fabre Medicament |
Receptor for vista
|
|
EP3844276A2
(en)
|
2018-08-28 |
2021-07-07 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
KR20210070300A
(ko)
|
2018-10-03 |
2021-06-14 |
스태튼 바이오테크놀로지 비.브이. |
사람 및 시노몰구스 ApoC3에 대해 특이적인 항체 및 이의 사용 방법
|
|
US12459995B2
(en)
|
2018-10-16 |
2025-11-04 |
Neuracle Science Co., Ltd. |
Use of anti-FAM19A5 antibodies
|
|
CN113286591A
(zh)
|
2018-11-01 |
2021-08-20 |
库拉肿瘤学公司 |
用法尼基转移酶抑制剂治疗癌症的方法
|
|
CN113365650A
(zh)
|
2018-11-16 |
2021-09-07 |
新免疫技术有限公司 |
用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
|
|
WO2020118042A1
(en)
|
2018-12-05 |
2020-06-11 |
Jacobs Wagner Christine |
Borrelia burgdorferi peptidoglycan as a diagnostic and target for therapeutic intervention of lyme disease-related pathologies
|
|
US12391705B2
(en)
|
2018-12-19 |
2025-08-19 |
Shy Therapeutics, Llc |
Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2020128033A1
(en)
|
2018-12-20 |
2020-06-25 |
Institut Pasteur |
Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
|
|
AU2019403379A1
(en)
|
2018-12-21 |
2021-07-15 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
|
KR20240000655A
(ko)
|
2018-12-27 |
2024-01-02 |
주식회사 뉴라클사이언스 |
죽상경화증을 치료하기 위한 항-fam19a5 항체의 사용
|
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
SG11202106244RA
(en)
|
2018-12-28 |
2021-07-29 |
Catalyst Biosciences Inc |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
|
EP3906260A4
(en)
|
2019-01-02 |
2022-08-31 |
Neuracle Science Co., Ltd |
SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5 AND METHOD OF USE THEREOF
|
|
TWI839461B
(zh)
|
2019-02-06 |
2024-04-21 |
美商戴斯阿爾法股份有限公司 |
Il-17a調節物及其用途
|
|
CN113874081A
(zh)
|
2019-02-26 |
2021-12-31 |
茵思博纳公司 |
高-亲和力抗-mertk抗体及其用途
|
|
WO2020176809A1
(en)
|
2019-02-27 |
2020-09-03 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
US12024709B2
(en)
|
2019-02-27 |
2024-07-02 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
|
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
IL286149B2
(en)
|
2019-03-07 |
2025-02-01 |
Histogen Inc |
CASPASE INHIBITORS AND METHODS OF USING THEM
|
|
WO2020190604A1
(en)
|
2019-03-15 |
2020-09-24 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
SG11202110472WA
(en)
|
2019-03-29 |
2021-10-28 |
Kura Oncology Inc |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
WO2020205387A1
(en)
|
2019-04-01 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
BR112021020864A2
(pt)
|
2019-04-19 |
2021-12-14 |
Ligand Pharm Inc |
Formas cristalinas e métodos de produção de formas cristalinas de um composto
|
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
WO2020236818A1
(en)
|
2019-05-20 |
2020-11-26 |
Nirvana Sciences Inc. |
Narrow emission dyes, compositions comprising same, and methods for making and using same
|
|
JP2022532925A
(ja)
|
2019-05-20 |
2022-07-20 |
ニルバナ サイエンシーズ インク． |
発光波長の範囲が狭い発光染料、それを含む組成物及びそれを製造及び使用する方法
|
|
CN114585644A
(zh)
|
2019-08-30 |
2022-06-03 |
艾吉纳斯公司 |
抗cd96抗体及其使用方法
|
|
CA3154608A1
(en)
|
2019-09-16 |
2021-03-25 |
Dice Alpha, Inc. |
Il-17a modulators and uses thereof
|
|
EP4613276A3
(en)
|
2019-11-12 |
2025-12-17 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
|
|
KR20220150274A
(ko)
|
2020-01-13 |
2022-11-10 |
네오이뮨텍, 인코퍼레이티드 |
Il-7 단백질과 이중특이적 항체의 조합물을 사용한 종양의 치료 방법
|
|
WO2021158783A1
(en)
|
2020-02-05 |
2021-08-12 |
Washington University |
Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
|
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2022006228A1
(en)
|
2020-06-30 |
2022-01-06 |
Prosetta Biosciences, Inc. |
Isoquinoline derivatives, methods of synthesis and uses thereof
|
|
EP4196139A2
(en)
|
2020-08-12 |
2023-06-21 |
Actym Therapeutics, Inc. |
Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
|
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
|
US20230398184A1
(en)
|
2020-10-26 |
2023-12-14 |
Neoimmunetech, Inc. |
Methods of inducing stem cell mobilization
|
|
WO2022094475A1
(en)
|
2020-11-02 |
2022-05-05 |
Neoimmunetech, Inc. |
Use of interleukin-7 for the treatment of coronavirus
|
|
CA3195594A1
(en)
|
2020-11-05 |
2022-05-12 |
Byung Ha Lee |
Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
|
|
US20240124483A1
(en)
|
2021-01-27 |
2024-04-18 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
US20240309015A1
(en)
|
2021-01-27 |
2024-09-19 |
Shy Therapeutics, Llc |
Methods for the Treatment of Fibrotic Disease
|
|
MX2023010545A
(es)
|
2021-03-10 |
2023-11-24 |
Dice Molecules Sv Inc |
Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos.
|
|
EP4326721A1
(en)
|
2021-04-22 |
2024-02-28 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
EP4355776A1
(en)
|
2021-06-14 |
2024-04-24 |
Argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
|
CA3236150A1
(en)
|
2021-10-22 |
2023-04-27 |
Prosetta Biosciences, Inc. |
Novel host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
KR20240115979A
(ko)
|
2021-11-08 |
2024-07-26 |
프로젠토스 테라퓨틱스, 인크. |
혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
|
|
KR20240130705A
(ko)
|
2021-12-30 |
2024-08-29 |
네오이뮨텍, 인코퍼레이티드 |
Il-7 단백질 및 vegf 길항제의 조합으로 종양을 치료하는 방법
|
|
EP4433040A4
(en)
|
2022-01-03 |
2025-11-12 |
Lilac Therapeutics Inc |
ACYCLIC THIOL PRODRUGS
|
|
US11932665B2
(en)
|
2022-01-03 |
2024-03-19 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
CA3253352A1
(en)
|
2022-03-02 |
2023-09-07 |
Mitopower, Inc. |
NEW PROMEDICINAL PRODUCTS DERIVED FROM NICOTINIC ACID AND RIBOSE
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
WO2023201282A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Novel gspt1 compounds and methods of use of the novel compounds
|
|
EP4507720A1
(en)
|
2022-04-14 |
2025-02-19 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
|
|
US20240209100A1
(en)
|
2022-10-21 |
2024-06-27 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
|
WO2024092040A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing bicyclic heteroaryl compounds
|
|
WO2024092037A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
|
US20240174673A1
(en)
|
2022-10-26 |
2024-05-30 |
Protego Biopharma, Inc. |
Spirocycle Containing Pyridine Compounds
|
|
EP4615485A1
(en)
|
2022-11-07 |
2025-09-17 |
NeoImmuneTech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|
|
EP4626864A1
(en)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
WO2024118810A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Cyclic pyrazole diamide ire1/xbp1s activators
|
|
WO2024194686A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
CN121057752A
(zh)
|
2023-04-07 |
2025-12-02 |
达科纳治疗有限公司 |
铰链经修饰的双特异性抗体
|
|
WO2024211796A1
(en)
|
2023-04-07 |
2024-10-10 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
|
|
WO2024226471A2
(en)
|
2023-04-24 |
2024-10-31 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating stxbp1 disorders
|
|
AU2024269869A1
(en)
|
2023-05-09 |
2025-10-16 |
Progentos Therapeutics, Inc. |
Heterocyclic compounds and uses thereof
|
|
US20250019450A1
(en)
|
2023-05-19 |
2025-01-16 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to il12 receptor
|
|
WO2025010272A1
(en)
|
2023-07-03 |
2025-01-09 |
Neoimmunetech, Inc. |
Heterodimeric fc molecules and uses thereof
|
|
WO2025049818A1
(en)
|
2023-08-29 |
2025-03-06 |
Enosi Therapeutics Corporation |
Tnfr1 antagonists lacking agonist activity and uses thereof
|
|
TW202515919A
(zh)
|
2023-09-01 |
2025-04-16 |
比利時商艾托斯比利時公司 |
抗ｔｒｅｍ２抗體及使用方法
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
US20250122182A1
(en)
|
2023-09-27 |
2025-04-17 |
Isosterix, Inc. |
MYST Inhibitors
|
|
WO2025085416A1
(en)
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the compounds
|
|
US20250179197A1
(en)
|
2023-10-23 |
2025-06-05 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
WO2025133707A1
(en)
|
2023-12-19 |
2025-06-26 |
Vectory Therapeutics B.V. |
Anti-tdp-43 antibodies and uses thereof
|
|
WO2025147691A1
(en)
|
2024-01-04 |
2025-07-10 |
Innovo Therapeutics, Inc. |
Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025201633A1
(en)
|
2024-03-26 |
2025-10-02 |
Chen Gefei |
An agent for reducing amyloid formation
|
|
WO2025255341A1
(en)
|
2024-06-05 |
2025-12-11 |
Protego Biopharma, Inc. |
Tetrahydrofuranyl ire1/xbp1s activators
|